This article is more than 5 years old. Information may no longer be current.

Health Canada accepts new drug submission for Iluvien for DME

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

A new drug submission for Iluvien has been accepted for review by Health Canada, according to a press release from Knight Therapeutics and Alimera Sciences.

Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg, Alimera) sustained-release intravitreal implant is already approved in the U.S. to treat diabetic macular edema in patients who were previously treated with corticosteroids.

The two companies signed an agreement in July 2015 for Knight to have the exclusive right to distribute the treatment in Canada.